Skip to main content

IOC Banned Drugs and their Effects on the Cardiovascular System

  • Chapter
Advances in Sports Cardiology
  • 58 Accesses

Abstract

Doping is defined as the administration or intentional use of substances external to the body, however they are introduced, or as measures taken by an athlete before or during a sporting event with the aim of artificially and illegally improving his sporting Performance [18]. Physical Performance is physiologically activated by means of the intense Stimulation of all or nearly all the organs or apparatuses of the human body. This is particularly true for the cardiocirculatory System. There is no activity which does not require the immediate Support of blood circulation, and so any substance capable of ergotropically modifying the physical Performance has to act by stimulating the cardiocirculatory system. Many of them are normal deposit-releasing chemical mediators of cardiovascular ergotropic Stimuli, that are usually synthesised and metabolised in the human body, but the majority are substances which are not present physiologically but can indirectly stimulate active cardiac and vessel receptors. In the first group, the Stimuli are physiologically similar to those which normally occur during training sessions designed to improve gradually the responses of neuromodellers and so their artificial introduction into the circulation differs from normal physiology only in terms of their sudden effect and the lack of preparation on the part of the body as a whole; the substances in the second group have a reflex action which is accompanied by the large number of side effects which are themselves toxic for the organism.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Antonaccio MJ (1980) Farmacologia clinica cardiovascolare. Martinucci Ed

    Google Scholar 

  2. Appleby M, Eischer M, Martin M (1994) Myocardial infarction, hyperkalemia and ventricular tachicardia in young male body builder. J Cardiol 44:171–174

    CAS  Google Scholar 

  3. Bruno M (1990) Gli steroidi anabolizzanti ed il loro abuso nella pratica sportiva Clin Ter 135:159–72

    PubMed  CAS  Google Scholar 

  4. Celotti F, Negri-Cesi P (1992) Anabolic Steroids. J Steroid Biochem Mol Biol 43:469–11

    Article  PubMed  CAS  Google Scholar 

  5. Cheever K, House Ma (1992) Cardiovascular implication of anabolic Steroid abuse. J Cardiovasc Nurs 6:19–30

    PubMed  CAS  Google Scholar 

  6. Di Biase G, Labriola E (1966) Le catecolamine e Papparato cardiovascolare. Patrou Ed

    Google Scholar 

  7. Ferenchick GS (1991) Anabolic/androgenic Steroid abusewith cardiomyopaty in atlet. Am J Med 92:562

    Article  Google Scholar 

  8. Ferenchick GS (1991) Anabolic/andogenic Steroid abuse and thrombosis, is there a connection? Med Hypotheses 35:27

    Article  PubMed  CAS  Google Scholar 

  9. Haupt HA (1993) Anabolic Steroid and growth hormone. Am J Sport Med 21:468–74

    Article  CAS  Google Scholar 

  10. Katz AM (1981) Fisiologia del cuore. Cortina Ed

    Google Scholar 

  11. Kennedy MC, Lawrence C (1993) Anabolic Steroid abuse and cardiac death. Med J Aust 158:346–8

    PubMed  CAS  Google Scholar 

  12. Jensen LK (1994) Biviz Kninger oy dopingcontrol Ved lrug of anabolic Steroid. Vgeskr-Laeger 156:58723–3

    Google Scholar 

  13. Luke JL et al (1990) Sudden cardiac death during exercise in a weight-ligter using anabolic Steroids. J Forensic Sei 35:1441–7

    CAS  Google Scholar 

  14. Schimd P (1990) Der Einsatz von Beta-Rezeptors-Blockern in Leistungssport. Wien Med Wochenschr 140:184–8

    Google Scholar 

  15. Smith DA, Perry PJ (1992) The efficacy of ergonogenic agents in athletic competition. Ann Pharmacother 26:520–8

    PubMed  CAS  Google Scholar 

  16. Thomson PD et al (1992) Left ventricular funetion is not impaired in weightlifters who use anabolic Steroids. J Am Coli Cardiol 9:278–82

    Article  Google Scholar 

  17. Venerando A, Zeppilli P (1982) Cardiologia dello sport. Masson Ed

    Google Scholar 

  18. Vecchiet L, Calligaris A, Montanari G, Resina A (1990) Trattato di medicina dello sport applicata al calcio. Menarini Ed

    Google Scholar 

  19. Weider AA, Melchert RE (1993) Cardiotoxiceffects of cocaine and anabolic-androgenic Steroids in the athlete. J Pharmacol-Toxical Methods 29:61–8

    Article  Google Scholar 

  20. Zeppilli. Cuore d’atleta. Master Pharma Ed

    Google Scholar 

  21. Zinzen E, Clariys JP, Vanderstappen D, Vandenberg YJ (1994) The influence of triazolam and flunitruzepam an isokinetic and isometri muscle Performance Ergonomics 37:69–77

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer-Verlag Italia

About this chapter

Cite this chapter

Montemartini, C., Iraghi, G. (1997). IOC Banned Drugs and their Effects on the Cardiovascular System. In: Pelliccia, A., Caselli, G., Bellotti, P. (eds) Advances in Sports Cardiology. Springer, Milano. https://doi.org/10.1007/978-88-470-2298-0_23

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-2298-0_23

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-3-540-75036-9

  • Online ISBN: 978-88-470-2298-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics